Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, with > 500,000 new cases annually, and it is the second leading cause of cancer-related mortality worldwide (1, 2) . The incidence of HCC is increasing worldwide and especially in AsianPacific countries, and half of all cases occur in China (3) . HCC with bile duct tumor thrombus (BDTT) is rarely seen in clinical practice, and its incidence has been reported to be 1.2-12.9% (4) (5) (6) (7) (8) (9) . Due to a lack of awareness of HCC with BDTT, some patients fail to receive effective treatment. This is especially true for those with obstructive jaundice who are considered to be in the late stage of tumor progression.
The principle for surgical treatment of HCC with BDTT is the removal of primary HCC and BDTT, and active surgical resection may benefit patients (10) (11) (12) . Patients with HCC and BDTT may undergo radical resection, thrombectomy through a choledochotomy, palliative internal and external bile duct drainage, or transarterial chemoembolization (TACE) depending on the type of BDTT. However, the treatment strategies and prognosis for patients with HCC with BDTT are still a subject of debate (13, 14) .
To ascertain the characteristics of and prognosis for HCC with BDTT, clinical features of and surgical outcomes for patients who underwent different surgical treatments were retrospectively analyzed. The prognostic factors associated with long-term survival for patients with HCC with BDTT who underwent radical resection were also analyzed in this study.
Patients and Methods

Patients
From Results of diagnostic ultrasonography were positive in 14.29% of patients (7/49), CT results were positive in 35.00% (14/40), and MRCP results were positive in 59.18% (29/49). A biliary tumor thrombus was diagnosed with ERCP at a rate of 100% (8/8).
The tumor thrombus was histopathologically examined in patients with HCC with BDTT who underwent surgical treatment ( Figure 2 ). HCC with BDTT was divided into the following categories: a simple tumor thrombus and a blood clot mixed with a tumor thrombus. The BDTT was yellowish, brownish, or purplish-black in color and had a pathological type identical to that of a hepatic primary tumor. According to the Ueda classification of HCC with BDTT, 2 patients had type I tumors, 2 had type II, 42 had type III, and 3 had type IV.
Surgical treatment
Twenty-five patients underwent radical resection, 7 underwent thrombectomy through a choledochotomy, and 17 underwent palliative internal and external bile duct drainage ( Figure 1) .
Out of 25 patients who underwent radical resection, 2 had type I tumors, 2 had type II, and 21 had type III according to the Ueda classification. Seventeen patients underwent hemihepatectomy, including 11 who underwent hemihepatectomy plus thrombectomy through a choledochotomy ( Figure 3A ) and 6 who underwent biliary reconstruction ( Figure 3B and 3C). Of the 6 patients who underwent biliary reconstruction, 5 underwent hemihepatectomy plus extrahepatic bile duct resection plus cholangiojejunostomy and 1 underwent left hemihepatectomy plus common hepatic duct resection plus end-to-end anastomosis of the right hepatic duct to the common bile duct. In addition, 8 patients in this group underwent HCC resection plus thrombectomy through a choledochotomy due to severe cirrhosis ( Figure  3D ), and the surgical margin was greater than 1 cm.
Seven patients underwent thrombectomy through a obstruction or stenosis of the biliary trees. The tumor thrombus was histopathologically examined in patients with HCC with BDTT who underwent surgical treatment.
The Ueda (6) classification of HCC with BDTT was used in this study: i) type I: BDTT located in the secondary branch of the bile duct tree; ii) type II: BDTT extending to the first branch of the bile duct tree; iii) type IIIa: BDTT extending to the common hepatic duct; type III: an implanted tumor growing in the CBD, and iv) type IV: floating tumor debris from the ruptured tumor in CBD (15).
Treatment strategies
Resectability was determined based on the patient's general condition, tumor status, pre-operative liver function tests, preoperative diagnosis of the location of the primary tumors, extension of BDTT, and the future remnant liver parenchyma.
Patients with HCC with BDTT who had an unresectable tumor or in whom a lesion could not be found underwent thrombectomy through a choledochotomy.
Patients with advanced disease or disease complicated by chronic diseases and without surgical indications underwent palliative internal and external bile duct drainage (PTCD, ERCP, or intraductal stent drainage) or TACE.
Follow-up
During the first 3 months after surgical treatment, patients were re-examined every month. Afterwards, patients were re-examined every 3 months. Clinical, laboratory, and radiological data were collected during each follow-up visit.
All patients were followed until October 2018. Survival was measured from the time of surgical treatment, and death was the endpoint.
Statistical analysis
The statistical software SPSS 19.0 was used for statistical analysis. The life table method was used to estimate the survival rate, and the survival analysis was based on the log-rank (Mantel-Cox) method. Quantitative data are expressed as the mean ± standard deviation (mean ± S.D.). Qualitative data were tested using the Chi-square test. Statistical significance was defined as a p value < 0.05.
Results
Clinicopathological data
Forty-nine patients with HCC and BDTT were enrolled choledochotomy, including 4 with type III tumors and 3 with type Ⅳ according to the Ueda classification. A total of 17 patients underwent palliative internal and external bile duct drainage, including 5 who underwent ERCP plus biliary stenting, 4 who underwent TACE, 3 who underwent PTCD, 2 who underwent ERCP plus TACE, 2 who underwent PTCD plus TACE, and 1 who underwent PTCD plus ERCP. All 17 patients had type III tumors according to the Ueda classification.
Perioperative outcome
The operating time, intraoperative blood loss, rate of blood transfusion, duration of postoperative hospitalization, surgical complications, and mortality for the 25 patients who underwent radical resection and 7 patients who underwent thrombectomy through a choledochotomy are shown in Table 1 .
Two of these patients died of liver failure after surgery. Both of the 2 patients had intraoperative blood loss of greater than 1,500 mL, liver failure occurred 1 week after surgery, and they died within 2 months after surgery although they received supportive treatment including artificial liver support.
Eight patients developed surgical complications, including 2 who had gastric bleeding due to a stress ulcer and were cured after treatment, 3 who had subphrenic effusion, and 3 who had a pulmonary infection. All 8 patients recovered with treatment.
Prognosis: Survival
The 49 patients with HCC with BDTT had a 1-year survival rate of 42.86% (21/49), a 3-year survival rate of 18.37% (9/49), and a 5-year survival rate of 12.24% (6/49).
The 25 patients who underwent radical resection had a median survival of 19 months and a 1-year survival rate of 68.00% (17/25), a 3-year survival rate of 32.00% (8/25), and a 5-year survival rate of 24.00% (6/25).
The 7 patients who underwent thrombectomy through a choledochotomy had a median survival of 8 months and a 1-year survival rate of 28.57% (2/7), a 3-year survival rate of 14.29% (1/7), and a 5-year survival rate of 0% (0/7).
The 17 patients who underwent palliative internal and external bile duct drainage had a median survival of 3 months and a 1-year survival rate of 5.89% (1/17), a 3-year survival rate of 0% (0/17) (1/7), and a 5-year survival rate of 0% (0/17).
The survival curves for patients who received above different treatments are shown in Figure 4 (p < 0.001). Out of 25 patients who underwent radical resection, 6 without portal vein and hepatic vein tumor thrombus are still alive with a long-term survival of more than 60 months (Table 2 ). Of the 6 patients, 4 lived for 120 months, and the longest survival was 172 months to date. No portal or hepatic vein tumor thrombi were found in these patients. Of these patients, patient 1 underwent HCC resection (junction of segments III and IV) plus thrombectomy through a choledochotomy. Recurrence of a thrombus in the left hepatic duct 6 months after surgery resulted in multiple tumors in the residual left lobe of the liver. Left hemihepatectomy plus liver hilar bile duct resection with right Roux-en-Y hepaticojejunostomy was performed. The patient has survived 172 months after surgery. Patient 4 was diagnosed with HCC of right hepatic segment VII 65 months after surgery and underwent TACE. No new lesions were detected during the 61 months of follow-up. The patient has survived 126 months after surgery. Patient 5 was the only patient with a type II tumor who recovered considerably after surgery and who has survived 66 months after surgery. Patient 6 was a 15-year-old patient who underwent left hemihepatectomy plus common hepatic duct resection with end-to-end anastomosis of the right hepatic duct to the common bile duct. The biliary tract was reconstructed during surgery, and the patient has survived for 63 months.
Prognostic factors for long-time survival of patients who underwent radical resection
Analysis with the Mantel-Cox model indicated that the preoperative bilirubin level (p = 0.025), intraoperative blood loss (p = 0.006), tumor size (p = 0.005), and presence of portal and hepatic vein tumor thrombi (p = 0.021) were significant prognostic factors associated with long-term survival for patients who underwent radical resection in this study (Table 3) .
Discussion
Of 49 patients with HCC with BDTT, 25 underwent radical resection, 7 underwent thrombectomy through a choledochotomy, and 17 underwent palliative internal and external bile duct drainage. Patients who underwent a radical resection had a better prognosis than patients in the other two groups (p < 0.001). Moreover, the preoperative bilirubin level, intraoperative blood loss, tumor size, and presence of portal and hepatic vein tumor thrombi were identified as prognostic factors associated with long-term survival for patients who underwent a radical resection
The principle for surgical treatment of HCC with BDTT is the removal of primary HCC and BDTT. Active surgical resection may benefit patients (10-12). A higher rate of resection is associated with significantly prolonged survival for some patients (16, 17) . At the current authors' facility, the surgical procedure and scope of resection depend on the patient's liver reserve function, residual liver volume, and Ueda classification. Depending on the patient's condition, routine PTCD or endoscopic nasobiliary drainage (ENBD) was performed before surgery to reduce the degree of jaundice, and different types of liver resection were performed during surgery. Most cases of HCC with BDTT were classified as category Ueda type III. The formation of a tumor thrombus in the ipsilateral bile duct with contralateral compensatory enlargement of the liver (i.e., atrophichypertrophic syndrome) makes tumor resection easier.
The surgical plan should be individually based on the degree of the close relationship between the tumor thrombus and extrahepatic biliary duct. Depending on the location of the HCC and BDTT, HCC resection or hemihepatectomy plus thrombectomy through choledochotomy is chosen. In cases where the BDTT is firmly attached to or even invades the extrahepatic bile duct wall, extrahepatic bile duct resection should be considered (15, 18, 19) . In the current study, 2 patients who underwent HCC resection and thrombectomy through a choledochotomy had recurrence of the tumor thrombus in the left hepatic duct within 6 months after surgery, which resulted in multiple tumors in the residual left lobe of the liver. Further surgery, such as hemi hepatectomy, hilar biliary duct resection, or Roux-en-Y hepaticojejunostomy, was performed. Intraoperative cholangioscopy was used to rule out the presence of a tumor thrombus in the intrahepatic distal bile duct and as an important examination to prevent recurrence. At present, the 2 patients who underwent further surgery are in satisfactory condition. This finding indicates that surgery remains an effective treatment for tumor recurrence. Liver hilar lymph node dissection was performed in 7 patients, but metastatic lymph nodes were not noted. Thus, additional studies with larger samples need to be performed to decide whether to routinely perform hilar lymph node dissection in patients with HCC with BDTT.
Two patients of the current patients (intraoperative blood loss > 1,500 mL) had liver failure and died within 2 months after surgery after the failure of artificial liver support and other treatments. Preoperative preparation should be sufficient, with particular attention devoted to reducing the preoperative bilirubin level (and especially the direct bilirubin level), retention of an adequate residual liver volume, and reduction of intraoperative blood loss. These key factors affect patients perioperatively.
Patients with HCC with BDTT for which radical surgery is not indicated should have external and internal hepatobiliary drainage tubes placed via PTCD or ENBD and undergo bile duct stenting to reduce the degree of jaundice and alleviate pruritis. Transarterial embolization may be another option in this case (16, 20) .
A comparative analysis of HCC with BDTT versus HCC without BDTT by Rammohan et al. (21) indicated that the degree of preoperative jaundice and tumor size were important factors affecting prognosis. This result was consistent with the current finding that the degree of preoperative jaundice was the main factor influencing long-term survival (p < 0.05). Analysis of the 25 patients in the current study indicated that intraoperative blood loss and portal vein and hepatic vein tumor thrombi were the main factors influencing long-term survival (p < 0.05). A vascular tumor thrombus was not noted in the 6 patients surviving long term (more than 60 months).
Conclusion
Surgical radical resection is the key to a favorable prognosis for patients with HCC with BDTT. In the current study, the preoperative bilirubin level, intraoperative blood loss, tumor size, and presence of portal and hepatic vein tumor thrombi were significant prognostic factors associated with long-term survival for patients who underwent radical resection. However, this study was retrospective, it had a small sample size, and it was conducted at a single center. Multicenter, prospective studies with a larger sample need to be conducted to verify the effectiveness of radical resection.
Radical resection should be performed with adequate preoperative preparation for patients with HCC with BDTT in whom surgery is not contraindicated. If radical resection is not indicated, then thrombectomy through a choledochotomy or internal and external drainage of the biliary duct and TACE should be performed to alleviate symptoms, improve quality of life, and promote longer survival.
